OH Epic Formulary, available in Epic via therapy plan, restricted to:

• Indication: Primary progressive multiple sclerosis (PPMS) or relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease
• Service line: Neurology
• Formulary location: Outpatient
• Service location: Outpatient Infusion, Home Infusion
• Patient population: Adults (≥ 18 years)
• Prior authorization required: Yes
• Restriction/criteria of use (all will apply unless specified):
  • Diagnosis of primary progressive multiple sclerosis (PPMS) or relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
  • Not concomitantly receiving other disease modifying therapies (DMTs) for multiple sclerosis (MS)
  • No active Hepatitis B Virus infection
  • Females of reproductive potential should use effective contraception while receiving ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo) and for 6 months after the last dose of ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo)
  • Require testing for quantitative serum immunoglobulins
  • All immunizations administered according to immunization guidelines at least 4 weeks prior to initiation of ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo) for live or live- attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo) for non-live vaccines

• UpToDate
• Lexicomp
• DailyMed Package Inserts
• Johns Hopkins Guides